MX2023001358A - N´-(2-cloro-6-metilbenzoil)-4-metil-3-[2-(3-quinolil) etinil]-benzohidrazida para el tratamiento de la enfermedad de alzheimer. - Google Patents
N´-(2-cloro-6-metilbenzoil)-4-metil-3-[2-(3-quinolil) etinil]-benzohidrazida para el tratamiento de la enfermedad de alzheimer.Info
- Publication number
- MX2023001358A MX2023001358A MX2023001358A MX2023001358A MX2023001358A MX 2023001358 A MX2023001358 A MX 2023001358A MX 2023001358 A MX2023001358 A MX 2023001358A MX 2023001358 A MX2023001358 A MX 2023001358A MX 2023001358 A MX2023001358 A MX 2023001358A
- Authority
- MX
- Mexico
- Prior art keywords
- benzohydrazide
- methylbenzoyl
- quinolyl
- ethynyl
- chloro
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 title 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 title 1
- ZQOBVMHBVWNVBG-UHFFFAOYSA-N 2-chloro-6-methyl-n'-[4-methyl-3-(2-quinolin-3-ylethynyl)benzoyl]benzohydrazide Chemical compound C1=C(C#CC=2C=C3C=CC=CC3=NC=2)C(C)=CC=C1C(=O)NNC(=O)C1=C(C)C=CC=C1Cl ZQOBVMHBVWNVBG-UHFFFAOYSA-N 0.000 abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 238000004220 aggregation Methods 0.000 abstract 2
- 230000002776 aggregation Effects 0.000 abstract 2
- 230000006951 hyperphosphorylation Effects 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención proporciona un método para prevenir o tratar la enfermedad de Alzheimer y sus síntomas, que comprende administrar a un sujeto que lo necesita una cantidad terapéuticamente eficaz de N'-(2-cloro-6-metilbenzoil)-4-metil-3-[ 2-(3-quinolil)etinil]-benzohidrazida o sus sales farmacéuticamente aceptables, en donde la prevención y/o el tratamiento de dicha enfermedad y sus síntomas se logran mediante la inhibición de la agregación de placas de beta amiloide (Aß), la hiperfosforilación de tau, la cinasa c-Abl o una combinación de estas. También se describe el uso de una cantidad terapéuticamente eficaz de N'-(2-cloro-6-metilbenzoil)-4-metil-3-[ 2-(3-quinolil)etinil]-benzohidrazida o sus sales farmacéuticamente aceptables para inhibir la agregación de placas de beta amiloide (Aß), la hiperfosforilación de tau, la cinasa c-Abl o una combinación de estas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202021032951 | 2020-07-31 | ||
| PCT/IB2021/056986 WO2022024072A1 (en) | 2020-07-31 | 2021-07-30 | N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl) ethynyl]-benzohydrazide for treatment of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001358A true MX2023001358A (es) | 2023-02-27 |
Family
ID=77265130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001358A MX2023001358A (es) | 2020-07-31 | 2021-07-30 | N´-(2-cloro-6-metilbenzoil)-4-metil-3-[2-(3-quinolil) etinil]-benzohidrazida para el tratamiento de la enfermedad de alzheimer. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230301982A1 (es) |
| EP (1) | EP4188351A1 (es) |
| JP (1) | JP2023536440A (es) |
| KR (1) | KR20230047140A (es) |
| CN (1) | CN116194098A (es) |
| AU (1) | AU2021317186A1 (es) |
| BR (1) | BR112023001330A2 (es) |
| CA (1) | CA3185939A1 (es) |
| CL (1) | CL2023000270A1 (es) |
| IL (1) | IL300044A (es) |
| MX (1) | MX2023001358A (es) |
| WO (1) | WO2022024072A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023214314A1 (en) | 2022-05-02 | 2023-11-09 | Sun Pharma Advanced Research Company Limited | Vodobatinib for reducing progression of parkinson's disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA024194B8 (ru) | 2011-01-21 | 2016-11-30 | Сан Фарма Адвансед Ресьорч Компани Лтд | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы |
| US10849887B2 (en) | 2016-06-02 | 2020-12-01 | Sun Pharma Advanced Research Company Ltd. | Treatment of Parkinson's disease |
| JP7234129B2 (ja) * | 2017-03-15 | 2023-03-07 | サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド | ４－メチル－３－キノリン－３－イルエチニル－安息香酸ｎ’－（２－クロロ－６－メチル－ベンゾイル）ヒドラジドの新規非晶質分散体 |
-
2021
- 2021-07-30 MX MX2023001358A patent/MX2023001358A/es unknown
- 2021-07-30 CA CA3185939A patent/CA3185939A1/en active Pending
- 2021-07-30 BR BR112023001330A patent/BR112023001330A2/pt unknown
- 2021-07-30 WO PCT/IB2021/056986 patent/WO2022024072A1/en active Application Filing
- 2021-07-30 IL IL300044A patent/IL300044A/en unknown
- 2021-07-30 EP EP21752214.3A patent/EP4188351A1/en active Pending
- 2021-07-30 JP JP2023505420A patent/JP2023536440A/ja active Pending
- 2021-07-30 KR KR1020237006846A patent/KR20230047140A/ko unknown
- 2021-07-30 US US18/018,438 patent/US20230301982A1/en active Pending
- 2021-07-30 AU AU2021317186A patent/AU2021317186A1/en active Pending
- 2021-07-30 CN CN202180061409.2A patent/CN116194098A/zh active Pending
-
2023
- 2023-01-27 CL CL2023000270A patent/CL2023000270A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116194098A (zh) | 2023-05-30 |
| BR112023001330A2 (pt) | 2023-02-14 |
| KR20230047140A (ko) | 2023-04-06 |
| EP4188351A1 (en) | 2023-06-07 |
| AU2021317186A1 (en) | 2023-03-16 |
| CL2023000270A1 (es) | 2023-09-29 |
| US20230301982A1 (en) | 2023-09-28 |
| IL300044A (en) | 2023-03-01 |
| JP2023536440A (ja) | 2023-08-25 |
| CA3185939A1 (en) | 2022-02-03 |
| WO2022024072A1 (en) | 2022-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000798A (es) | Peptidos funcionalizados como agentes antivirales. | |
| CR20210563A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| NZ527113A (en) | Rapid-onset medicament for the treatment of sexual dysfunction | |
| EA200501496A1 (ru) | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения | |
| MX2023005984A (es) | Nuevos agentes antivirales derivados de la espiropirrolidina. | |
| MX2023001756A (es) | Peptidos funcionalizados como agentes antivirales. | |
| EA008165B1 (ru) | Композиции для лечения простуды | |
| BR0111591A (pt) | Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes | |
| MX2023005983A (es) | Nuevos agentes antivirales derivados de la espiropirrolidina. | |
| CA2454976A1 (en) | Therapeutic agent for glaucoma comprising compound having pi3 kinase inhibitory action as active ingredient | |
| MX2023001358A (es) | N´-(2-cloro-6-metilbenzoil)-4-metil-3-[2-(3-quinolil) etinil]-benzohidrazida para el tratamiento de la enfermedad de alzheimer. | |
| AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
| MX2021013942A (es) | Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton. | |
| WO2021232067A8 (en) | Stat3 inhibition for treatment and prevention of human coronavirus infection | |
| CA2313270A1 (en) | Use of deferiprone in treating and preventing iron-induced cardiac disease | |
| Papadimitriou et al. | Therapy and prevention of affective illness by total sleep deprivation | |
| MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
| MX2022012135A (es) | Métodos para tratar la enfermedad de coronavirus de 2019. | |
| CA2641713A1 (en) | Hydrate forms of amg706 | |
| WO1999045909A3 (en) | Use of nitrone compounds for the inhibition of angiogenesis | |
| AR127533A1 (es) | INHIBIDORES DEL SARS-CoV-2 PARA EL TRATAMIENTO DE INFECCIONES POR CORONAVIRUS | |
| MX2023005462A (es) | Compuestos macrociclicos y metodos para usarlos. | |
| US4159332A (en) | Prevention of or reduction in severity of myocardial infarction | |
| US20050009893A1 (en) | Treatment of high blood pressure during the acute phase of a stroke | |
| EA202000298A1 (ru) | ПРОТИВОКОРОНАВИРУСНОЕ СРЕДСТВО ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ COVID-19 (SARS-CoV-2) И СПОСОБ ЛЕЧЕНИЯ |